PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3838767-5 1985 [3H]Thymidine incorporation was inhibited by NK-CIA-containing supernatants in HLA-DR+ but not HLA-DR- bone marrow cell populations stimulated to proliferative by colony-stimulating factor (CSF). Thymidine 4-13 colony stimulating factor 2 Homo sapiens 163-188 3932087-6 1985 Exposure of myeloblasts to CSF induced increased triatiated thymidine (3H-TdR) incorporation within a few hours, while TPA did not induce 3H-TdR incorporation by itself and was inhibitory to CSF-induced 3H-TdR uptake. Thymidine 60-69 colony stimulating factor 2 Homo sapiens 27-30 3838767-5 1985 [3H]Thymidine incorporation was inhibited by NK-CIA-containing supernatants in HLA-DR+ but not HLA-DR- bone marrow cell populations stimulated to proliferative by colony-stimulating factor (CSF). Thymidine 4-13 colony stimulating factor 2 Homo sapiens 190-193 6606982-1 1984 A variety of growth factors and lectins were tested; only colony-stimulating factors CSF-1, Interleukin 3, and a T-lymphocyte GM CSF induced colony formation in semisolid medium and stimulated thymidine incorporation in liquid culture. Thymidine 193-202 colony stimulating factor 2 Homo sapiens 126-132 51071-0 1975 3H-thymidine autoradiography of CSF cells in primary reticulum cell sarcoma of the brain. Thymidine 3-12 colony stimulating factor 2 Homo sapiens 32-35 219789-2 1979 When CSF lymphocytes from five patients with infections associated with these organisms were incubated with "correct" antigen there was increased incorporation of thymidine. Thymidine 163-172 colony stimulating factor 2 Homo sapiens 5-8 55487-0 1976 3H-thymidine autoradiography of the CSF cells in cases of non-neoplastic disease. Thymidine 3-12 colony stimulating factor 2 Homo sapiens 36-39 11535531-0 2001 Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF. Thymidine 91-93 colony stimulating factor 2 Homo sapiens 99-147 12368687-2 2002 A critical step in the development of DT(388)-GMCSF for clinical use in childhood and adolescent AML is to determine whether children and adolescents have preexisting antibodies to DT(388)-GMCSF due to childhood immunizations against diphtheria toxoid. Thymidine 38-40 colony stimulating factor 2 Homo sapiens 46-51 18827566-2 2008 In our phase I trial of DT-granulocyte macrophage colony stimulating factor (GMCSF), a truncated DT linked to human GMCSF, in relapsed or refractory acute myeloid leukemia, patients with high concentrations of preexisting anti-DT IgG (>2.5 microg/ml) had significantly lower DT-GMCSF concentrations. Thymidine 24-26 colony stimulating factor 2 Homo sapiens 77-82 18827566-2 2008 In our phase I trial of DT-granulocyte macrophage colony stimulating factor (GMCSF), a truncated DT linked to human GMCSF, in relapsed or refractory acute myeloid leukemia, patients with high concentrations of preexisting anti-DT IgG (>2.5 microg/ml) had significantly lower DT-GMCSF concentrations. Thymidine 24-26 colony stimulating factor 2 Homo sapiens 116-121 18827566-2 2008 In our phase I trial of DT-granulocyte macrophage colony stimulating factor (GMCSF), a truncated DT linked to human GMCSF, in relapsed or refractory acute myeloid leukemia, patients with high concentrations of preexisting anti-DT IgG (>2.5 microg/ml) had significantly lower DT-GMCSF concentrations. Thymidine 24-26 colony stimulating factor 2 Homo sapiens 116-121 18827566-2 2008 In our phase I trial of DT-granulocyte macrophage colony stimulating factor (GMCSF), a truncated DT linked to human GMCSF, in relapsed or refractory acute myeloid leukemia, patients with high concentrations of preexisting anti-DT IgG (>2.5 microg/ml) had significantly lower DT-GMCSF concentrations. Thymidine 97-99 colony stimulating factor 2 Homo sapiens 24-75 18827566-2 2008 In our phase I trial of DT-granulocyte macrophage colony stimulating factor (GMCSF), a truncated DT linked to human GMCSF, in relapsed or refractory acute myeloid leukemia, patients with high concentrations of preexisting anti-DT IgG (>2.5 microg/ml) had significantly lower DT-GMCSF concentrations. Thymidine 97-99 colony stimulating factor 2 Homo sapiens 77-82 18827566-2 2008 In our phase I trial of DT-granulocyte macrophage colony stimulating factor (GMCSF), a truncated DT linked to human GMCSF, in relapsed or refractory acute myeloid leukemia, patients with high concentrations of preexisting anti-DT IgG (>2.5 microg/ml) had significantly lower DT-GMCSF concentrations. Thymidine 97-99 colony stimulating factor 2 Homo sapiens 116-121 18827566-2 2008 In our phase I trial of DT-granulocyte macrophage colony stimulating factor (GMCSF), a truncated DT linked to human GMCSF, in relapsed or refractory acute myeloid leukemia, patients with high concentrations of preexisting anti-DT IgG (>2.5 microg/ml) had significantly lower DT-GMCSF concentrations. Thymidine 97-99 colony stimulating factor 2 Homo sapiens 116-121 18827566-3 2008 This study details the fate of anti-DT IgG during the patient"s treatment with DT-GMCSF and describes how we could lower anti-DT IgG concentrations and increase the patient"s exposure to DT-GMCSF. Thymidine 36-38 colony stimulating factor 2 Homo sapiens 82-87 18827566-3 2008 This study details the fate of anti-DT IgG during the patient"s treatment with DT-GMCSF and describes how we could lower anti-DT IgG concentrations and increase the patient"s exposure to DT-GMCSF. Thymidine 36-38 colony stimulating factor 2 Homo sapiens 190-195 18827566-3 2008 This study details the fate of anti-DT IgG during the patient"s treatment with DT-GMCSF and describes how we could lower anti-DT IgG concentrations and increase the patient"s exposure to DT-GMCSF. Thymidine 79-81 colony stimulating factor 2 Homo sapiens 82-87 18827566-3 2008 This study details the fate of anti-DT IgG during the patient"s treatment with DT-GMCSF and describes how we could lower anti-DT IgG concentrations and increase the patient"s exposure to DT-GMCSF. Thymidine 79-81 colony stimulating factor 2 Homo sapiens 190-195 18827566-7 2008 In two individuals in whom we measured DT-GMCSF concentrations on day 1 and day 5, we observed that a decrease in anti-DT IgG concentrations was associated with an increase in DT-GMCSF concentrations. Thymidine 39-41 colony stimulating factor 2 Homo sapiens 42-47 18827566-7 2008 In two individuals in whom we measured DT-GMCSF concentrations on day 1 and day 5, we observed that a decrease in anti-DT IgG concentrations was associated with an increase in DT-GMCSF concentrations. Thymidine 39-41 colony stimulating factor 2 Homo sapiens 179-184 18827566-9 2008 For patients with high baseline anti-DT IgG concentrations, a single dose of DT-GMCSF could be used to lower the anti-DT IgG concentrations and potentially result in a significant increase in DT-GMCSF concentrations and efficacy. Thymidine 37-39 colony stimulating factor 2 Homo sapiens 80-85 18827566-9 2008 For patients with high baseline anti-DT IgG concentrations, a single dose of DT-GMCSF could be used to lower the anti-DT IgG concentrations and potentially result in a significant increase in DT-GMCSF concentrations and efficacy. Thymidine 77-79 colony stimulating factor 2 Homo sapiens 80-85 18827566-9 2008 For patients with high baseline anti-DT IgG concentrations, a single dose of DT-GMCSF could be used to lower the anti-DT IgG concentrations and potentially result in a significant increase in DT-GMCSF concentrations and efficacy. Thymidine 77-79 colony stimulating factor 2 Homo sapiens 195-200 12368687-11 2002 Preliminary results of the phase 1 trial of DT -GMCSF in adults with AML indicate that patients with baseline anti-DT(388)-GMCSF IgG concentrations of less than 2 microg/mL can achieve circulating DT(388)-GMCSF concentrations and can exhibit antileukemic activity. Thymidine 44-46 colony stimulating factor 2 Homo sapiens 48-53 12368687-11 2002 Preliminary results of the phase 1 trial of DT -GMCSF in adults with AML indicate that patients with baseline anti-DT(388)-GMCSF IgG concentrations of less than 2 microg/mL can achieve circulating DT(388)-GMCSF concentrations and can exhibit antileukemic activity. Thymidine 44-46 colony stimulating factor 2 Homo sapiens 123-128 12368687-11 2002 Preliminary results of the phase 1 trial of DT -GMCSF in adults with AML indicate that patients with baseline anti-DT(388)-GMCSF IgG concentrations of less than 2 microg/mL can achieve circulating DT(388)-GMCSF concentrations and can exhibit antileukemic activity. Thymidine 44-46 colony stimulating factor 2 Homo sapiens 123-128 12368687-11 2002 Preliminary results of the phase 1 trial of DT -GMCSF in adults with AML indicate that patients with baseline anti-DT(388)-GMCSF IgG concentrations of less than 2 microg/mL can achieve circulating DT(388)-GMCSF concentrations and can exhibit antileukemic activity. Thymidine 115-117 colony stimulating factor 2 Homo sapiens 48-53 12368687-11 2002 Preliminary results of the phase 1 trial of DT -GMCSF in adults with AML indicate that patients with baseline anti-DT(388)-GMCSF IgG concentrations of less than 2 microg/mL can achieve circulating DT(388)-GMCSF concentrations and can exhibit antileukemic activity. Thymidine 115-117 colony stimulating factor 2 Homo sapiens 123-128 12368687-11 2002 Preliminary results of the phase 1 trial of DT -GMCSF in adults with AML indicate that patients with baseline anti-DT(388)-GMCSF IgG concentrations of less than 2 microg/mL can achieve circulating DT(388)-GMCSF concentrations and can exhibit antileukemic activity. Thymidine 115-117 colony stimulating factor 2 Homo sapiens 123-128 12368687-12 2002 Twenty-three of 34 (67.6%) children and adolescents had anti-DT(388)-GMCSF IgG concentrations less than 2 microg/mL. Thymidine 61-63 colony stimulating factor 2 Homo sapiens 69-74 11535531-0 2001 Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF. Thymidine 91-93 colony stimulating factor 2 Homo sapiens 149-155 11535531-0 2001 Enhanced ceramide generation and induction of apoptosis in human leukemia cells exposed to DT(388)-granulocyte-macrophage colony-stimulating factor (GM-CSF), a truncated diphtheria toxin fused to human GM-CSF. Thymidine 91-93 colony stimulating factor 2 Homo sapiens 202-208 11535531-1 2001 DT(388)-GM-CSF, a targeted fusion toxin constructed by conjugation of human granulocyte-macrophage colony-stimulating factor (GM-CSF) with the catalytic and translocation domains of diphtheria toxin, is presently in phase I trials for patients with resistant acute myeloid leukemia. Thymidine 0-2 colony stimulating factor 2 Homo sapiens 8-14 11535531-1 2001 DT(388)-GM-CSF, a targeted fusion toxin constructed by conjugation of human granulocyte-macrophage colony-stimulating factor (GM-CSF) with the catalytic and translocation domains of diphtheria toxin, is presently in phase I trials for patients with resistant acute myeloid leukemia. Thymidine 0-2 colony stimulating factor 2 Homo sapiens 76-124 11535531-1 2001 DT(388)-GM-CSF, a targeted fusion toxin constructed by conjugation of human granulocyte-macrophage colony-stimulating factor (GM-CSF) with the catalytic and translocation domains of diphtheria toxin, is presently in phase I trials for patients with resistant acute myeloid leukemia. Thymidine 0-2 colony stimulating factor 2 Homo sapiens 126-132 11535531-3 2001 After 48 hours with DT(388)-GM-CSF (10 nM), ceramide levels in HL-60/VCR cells rose 6-fold and viability fell to 10%, whereas GM-CSF alone was without influence. Thymidine 20-22 colony stimulating factor 2 Homo sapiens 28-34 11535531-5 2001 Examination of the time course revealed that protein synthesis decreased by about 50% and cellular ceramide levels increased by about 80% between 4 and 6 hours after addition of DT(388)-GM-CSF. Thymidine 178-180 colony stimulating factor 2 Homo sapiens 186-192 11535531-10 2001 Diphtheria toxin increased ceramide and decreased sphingomyelin in U-937 cells, a cell line extremely sensitive to diphtheria toxin; exposure to DT(388)-GM-CSF showed sensitivity at less than 1.0 pM. Thymidine 145-147 colony stimulating factor 2 Homo sapiens 153-159 8481510-9 1993 In 4 of these patients, thymidine suicide of GM-CSF- and IL-3-stimulated CFU-C ranged from 17% to 42%. Thymidine 24-33 colony stimulating factor 2 Homo sapiens 45-61 9345060-2 1997 AML samples from three patients were incubated in vitro with 100 ng/mL DT-GM-CSF for 48 hours, and AML cell kill was determined in a proliferation assay, a clonogenic assay colony-forming unit-AML (CFU-AML) and a quantitative long-term bone marrow (BM) culture ie, the leukemic-cobblestone area forming cell assay (L-CAFC). Thymidine 71-73 colony stimulating factor 2 Homo sapiens 74-80 9166423-11 1997 For all R280 mutants, the half-efficient concentrations of GM-CSF required for membrane (receptor binding) to nuclear events (c-fos promoter activation) and cell proliferation (thymidine incorporation) were in the same range, indicating that the threshold for biologic activity is governed mainly by the affinity of ligand-receptor interaction. Thymidine 177-186 colony stimulating factor 2 Homo sapiens 59-65 8844019-4 1996 It has also been reported that some cytokines, notably GM-CSF, potentiate the antiviral properties of thymidine analogs such as zidovudine (AZT) in vitro. Thymidine 102-111 colony stimulating factor 2 Homo sapiens 55-61 8289485-2 1994 Granulocyte-macrophage colony-stimulating factor (GM-CSF) was given for 72 h before commencing chemotherapy in 15 patients with relapsed or refractory acute myeloid leukaemia (AML) and in 11 patients serial bone marrows were taken for measurement of [3H]thymidine labelling index, Ki-67 positivity and maximal binding of 5-(SAENTA-x8)-fluorescein, a flow cytometry ligand which enumerates nucleoside transporter sites. Thymidine 254-263 colony stimulating factor 2 Homo sapiens 0-48 8187006-5 1994 Our experiments show that both GM-CSF and IL-3 can increase 3H-thymidine incorporation and cloning efficiency and reduce DNA synthesis time of H69 and, to a lesser extent, N417 cells, supporting the hypothesis that hematopoietic growth factors can stimulate the growth of some malignant nonhematopoietic cells in vitro. Thymidine 63-72 colony stimulating factor 2 Homo sapiens 31-37 1482652-4 1992 These results were in contrast to the findings for colony stimulating activity and with GM-CSF induced thymidine uptake, where the biological activity was unchanged or reduced. Thymidine 103-112 colony stimulating factor 2 Homo sapiens 88-94 2646320-7 1989 CSF activity was observed in inflammatory SF, with tritiated thymidine uptake of 3,501 +/- 1,140 cpm in the presence of RA samples (n = 15) compared to 1,985 +/- 628 for non-RA inflammatory SF (n = 7) (P less than 0.05) and 583 +/- 525 for medium (n = 6) (P less than 0.01). Thymidine 61-70 colony stimulating factor 2 Homo sapiens 0-3 1613390-9 1992 In an [3H]thymidine incorporation assay with BM cells collected at different times of culture, d3 or d4 BM cells responded to human recombinant M-CSF, human recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF), bovine GM-CSF, murine M-CSF or murine M-CSF-containing supernatants, and bovine interleukin 1 beta (IL-1 beta) in decreasing order of magnitude. Thymidine 10-19 colony stimulating factor 2 Homo sapiens 169-217 1705306-6 1991 In short-term liquid cultures, IL-3, GM-CSF and G-CSF increased 3H-thymidine incorporation. Thymidine 67-76 colony stimulating factor 2 Homo sapiens 37-43 2155231-8 1990 Using the AML 193 [3H]thymidine incorporation assay the specific activity of the heavily glycosylated hGM-CSF was 1 x 10(8) units/mg compared with 6 x 10(8) units/mg for the non-glycosylated hGM-CSF produced by Escherichia coli. Thymidine 22-31 colony stimulating factor 2 Homo sapiens 102-109 1372056-4 1992 3H-thymidine uptake was markedly increased by the addition of GM-CSF in two cases, G-CSF in one, and IL-3 in two. Thymidine 3-12 colony stimulating factor 2 Homo sapiens 62-68 1824254-4 1991 IFN-gamma also inhibited M-CSF-, GM-CSF-, or IL-3-stimulated [3H]-thymidine incorporation in highly enriched GM-CFC. Thymidine 66-75 colony stimulating factor 2 Homo sapiens 33-39 1869822-2 1991 AM of healthy volunteers incubated with recombinant human GM-CSF revealed incorporation of [3H]thymidine in vitro. Thymidine 95-104 colony stimulating factor 2 Homo sapiens 58-64 1837466-6 1991 Loss of proliferative potential, in response to GM-CSF, was confirmed using [3H]-thymidine incorporation. Thymidine 81-90 colony stimulating factor 2 Homo sapiens 48-54 2182741-6 1990 Using the thymidine suicide technique, we observed that GM-CSF more than doubled the percentage of granulocyte-macrophage and megakaryocyte colony-forming units (CFU-gm and CFU-meg) and erythroid burst-forming units (BFU-e) in the S phase of the cell cycle. Thymidine 10-19 colony stimulating factor 2 Homo sapiens 56-62 2232847-3 1990 Preincubation with GM-CSF (0.01-0.1 microgram/ml) increased DNA synthesis as measured by tritiated thymidine incorporation and intranuclear Ki67 expression in cells from six persons with AML and in HL60 cells. Thymidine 99-108 colony stimulating factor 2 Homo sapiens 19-25 2546627-8 1989 The in vitro response of the cells to exogenous IL-3 or GM-CSF was examined by measuring thymidine uptake. Thymidine 89-98 colony stimulating factor 2 Homo sapiens 56-62 3264194-6 1988 On the other hand, in six cases, G-CSF enhanced the IL-3- or GM-CSF-stimulated thymidine uptake. Thymidine 79-88 colony stimulating factor 2 Homo sapiens 61-67